Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis

Bimekizumab, a humanized monoclonal IgG1 antibody targeting both interleukin (IL)-17A and IL-17F, could be effective for treating Psoriatic arthritis (PsA). This study aimed to systematically evaluate the efficacy and safety of bimekizumab in the management of PsA. A comprehensive literature search by August 2023 was performed through PubMed, Embase, Cochrane Controlled Register of Trials, and ClinicalTrials.gov. investigating the efficacy or safety data of bimekizumab in the treatment of PsA. Data was pooled using the random-effects models. Egger tests were used to evaluate potential publication bias. A total of 4 RCTs, involving 892 PsA patients and 467 placebo controls, were included in this analysis. Bimekizumab significantly increased the rates of PASI75 and PASI100 compared with placebos [RR = 7.22, 95% CI (5.24, 9.94), p &lt; 0.001; RR = 10.12, 95% CI (6.00, 17.09), <i>p</i> &lt; 0.001]. The rate of overall adverse events was slightly higher in the bimekizumab group [RR = 1.42, 95% CI (1.05, 1.93) <i>p</i> = 0.023). However, there were fewer adverse severe drug reactions in the bimekizumab group compared to the placebo. Bimekizumab had a significant clinical benefit in managing PsA and an acceptable safety profile.